Dear Editor,
We thank Drs. Cotton and Nicol for their letter [1] . They raise an important issue about maximizing the benefit and prolonging the efficacy of first-line antiretroviral therapy (ART) in sub-Saharan Africa during this time of rapid scaling-up to improve access to ART in the region [2] . We agree that improving adherence to first-line ART regimens is the best option to realize better treatment outcomes with the lowest cost in this resource-limited setting.
The second important point raised in their letter is that serious adverse drug reactions (ADRs) are prevalent and are associated with mortality and morbidity in patients taking ART [3, 4] . Severe ADRs that were more prevalent within the first 3 months were a barrier to achieving optimal adherence [4] , which is critically important for successful virological suppression in patients initiated on ART [5] .
We share the call of Drs Cotton and Nicol for rapid implementation of interventions to actively identify ADRs in patients who are initiated on ART [1] . However, it may be worth conducting a multicentre randomised controlled trial in resource-limited settings to test the effectiveness of various interventions to improve the detection and management of severe ART ADRs and thus improve treatment outcomes. Evidence-based strategies would assist the healthcare teams in ART clinics to reduce the influence of severe ADRs while the ART rollout expands in sub-Saharan Africa.
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